UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 5, 2007
Pipex Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation) |
01-12584 (Commission File Number) |
13-3808303 Identification Number) |
3930 Varsity Drive
Ann Arbor, MI 48108
(Address of principal executive offices) (Zip Code)
(734) 332-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
|
|_| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|_| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|_| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
|
|_| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
|
Item 8.01 |
Other Events. |
On November 5, 2007, the Registrant issued a press release reporting on its preliminary results using COPREXA™ in the most commonly utilized transgenic pre-clinical murine model of Alzheimer’s disease. The Registrant announced these results at the 2007 Society for Neuroscience annual meeting on November 4, 2007 in San Diego, California. The press release is furnished as an exhibit to this current report.
|
Item 9.01 |
Financial Statements and Exhibits |
|
|
|
|
(d) |
Exhibits
|
|
Exhibit No. |
Description
|
|
99.1 |
Press Release |
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PIPEX PHARMACEUTICALS, INC. |
|
|
|
|
Dated: November 5, 2007 |
By: /s/ Steve H. Kanzer Steve H. Kanzer Chairman and Chief Executive Officer |
|
|
|